Sagimet Biosciences (SGMT)

• Market cap: $196M
• 1 day: -3.21%
• 5 days: -2.58%
• 1 month: -22.79%
• 3 months: -5.19%
• 6 months: -18.51%
• Year to date: 34.3%
• 1 year: 5.24%
• 5 years: -62.19%
• 10 years: -62.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Employees: 14